Jump to content

IL Therapeutics

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Monkbot (talk | contribs) at 12:59, 27 November 2020 (Task 18 (cosmetic): eval 5 templates: del empty params (8×); hyphenate params (9×);). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

IL Therapeutics Inc.
IndustryBiotechnology
Headquarters105E ñ 111 Research Drive, Saskatoon, SK, Canada

IL Therapeutics Inc. was previously owned by Western Life Sciences Venture Fund LP ("Western Life Sciences") and in 2006 its shares were purchased by Pacgen Biopharmaceuticals Corporation ("Pacgen").[1][2]

History

Saskatchewan Research Council operates a bioprocessing laboratory which facilitated biomedical research. IL Therapeutics was developed from research first begun at the Western College of Veterinary Medicine.

Pharmaceuticals

Currently IL Therapeutics is working on a drug candidate, IL-8(3-73)K11R/G31P ("PAC-G31P") for relief of Acute Respiratory Distress Syndrome (ARDS).[1] The Saskatchewan Research council, SRC also assisted with the funding of this project through the Agriculture Development Fund - SRC Industry Venture Fund.[3] With the successful progression of G31P, the University of Saskatchewan Industry Liaison Office (ILO) decided to commercialize a commercialize this new drug treatment.[4] This research has been sponsored by a $3 million boost from the Western Life Sciences Venture Fund (WLS)[5]

See also

References

  1. ^ a b "Pacgen Biopharmaceuticals Acquires IL Therapeutics Inc" (PDF) (Press release). Pacgen Biopharmaceuticals. April 12, 2006. Archived from the original (PDF) on July 15, 2011. Retrieved August 11, 2018.
  2. ^ "Pacgen Biopharmaceuticals Acquires IL Therapeutics Inc". Pacgen Biopharmaceuticals. April 12, 2006. Retrieved August 11, 2018.
  3. ^ Saskatchewan Research Council 2005-2006 Annual Report. Sustainable Science Solutions. pp. 7–8. Archived from the original on July 6, 2011. Retrieved August 11, 2018.{{cite book}}: CS1 maint: numeric names: authors list (link)
  4. ^ U of S News Releases: University Communication, U of S News Releases: U of S Signs Letter of Intent to Commercialize Treatment for Lung Injury Complications, archived from the original on 2011-07-06, retrieved Sep 9, 2007
  5. ^ "U of S News Releases: U of S Spin-off gets $3 Million Boost to Develop Anti-inflammatory Drug" (PDF). Business View. Saskatoon and District Chamber of Commerce: 3. December 2004. Retrieved August 11, 2018.


Stub icon

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.

Stub icon

This Saskatchewan-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=IL_Therapeutics&oldid=990950373"